MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26

  • LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26

Dr. Daniel HengTom Baker Cancer Center, Calgary

More on genitourinary cancers

Everything on genitourinary cancers